Description
N-alpha-Tosyl-L-lysine chloromethyl ketone (TLCK), a trypsin like protease inhibitor, sensitizes HeLa cells to Fas-mediated cell death.
Product information
CAS Number: 4272-74-6
Molecular Weight: 369.31
Formula: C14H22Cl2N2O3S
Chemical Name: N-[(3S)-7-amino-1-chloro-2-oxoheptan-3-yl]-4-methylbenzene-1-sulfonamide hydrochloride
Smiles: Cl.CC1C=CC(=CC=1)S(=O)(=O)N[C@@H](CCCCN)C(=O)CCl
InChiKey: YFCUZWYIPBUQBD-ZOWNYOTGSA-N
InChi: InChI=1S/C14H21ClN2O3S.ClH/c1-11-5-7-12(8-6-11)21(19,20)17-13(14(18)10-15)4-2-3-9-16;/h5-8,13,17H,2-4,9-10,16H2,1H3;1H/t13-;/m0./s1
Technical Data
Appearance: Solid Power
Purity: ≥98% (or refer to the Certificate of Analysis)
Solubility: DMSO : 250 mg/mL (676.94 mM; Need ultrasonic).
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis
Storage Condition: Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.
Shelf Life: ≥12 months if stored properly.
Stock Solution Storage: 0 - 4 oC for 1 month or refer to the Certificate of Analysis.
Drug Formulation: To be determined
HS Tariff Code: 382200
How to use
In Vitro:
N-alpha-Tosyl-L-lysine chloromethyl ketone exhibits an inhibitory effect on IFN-γ activities. The effect of TLCK is studied on the IFN-γ sensitization of HeLa cells towards cell death mediated by anti-Fas. Lower concentration of anti-Fas (10 ng/mL) are used to examine the interaction among the three effectors simultaneously, that is, anti-Fas, TLCK and IFN-γ. TLCK by itself up to 50 μM concentration exhibits a small decrease in cell viability. Beyond 50 μM, a dose dependent decrease in cell viability is observed. IFN-γ slightly reduces cell viability on its own. Addition of anti-Fas (10 ng/mL) results in a slight decrease in cell survival, which is enhanced more than additively in the presence of TLCK, most prominently between 50 and 100 μM. Upon addition of both anti-Fas and IFN-γ, a decrease (≈46%) in cell viability is observed. Moreover, the decrease in cell survival is further enhanced upon addition of higher concentrations of TLCK, 25 μM and more.
References:
- Shadrin N, et al. Serine protease inhibitors interact with IFN-γ through up-regulation of FasR; a novel therapeutic strategy against cancer. Exp Cell Res. 2015 Jan 15;330(2):233-9.
Products are for research use only. Not for human use.
Payment & Security
Your payment information is processed securely. We do not store credit card details nor have access to your credit card information.